Literature DB >> 27858268

Misreporting of Product Adherence in the MTN-003/VOICE Trial for HIV Prevention in Africa: Participants' Explanations for Dishonesty.

Elizabeth T Montgomery1, B Mensch2, P Musara3, M Hartmann4, K Woeber5, J Etima6, A van der Straten4,7.   

Abstract

Consistent over-reporting of product use limits researchers' ability to accurately measure adherence and estimate product efficacy in HIV prevention trials. While lying is a universal characteristic of the human condition, growing evidence of a stark discrepancy between self-reported product use and biologic or pharmacokinetic evidence demands examination of the reasons research participants frequently misrepresent product use in order to mitigate this challenge in future research. This study (VOICE-D) was an ancillary post-trial study of the vaginal and oral interventions to control the epidemic (VOICE) phase IIb trial (MTN 003). It was conducted in three African countries to elicit candid accounts from former VOICE trial participants about why actual product use was lower than reported. In total 171 participants were enrolled between December 2012 and March 2014 in South Africa (n = 47), Uganda (n = 59) and Zimbabwe (n = 65). Data suggested that participants understood the importance of daily product use and honest reporting, yet acknowledged that research participants typically lie. Participants cited multiple reasons for misreporting adherence, including human nature, self-presentation with study staff, fear of repercussions (study termination resulting in loss of benefits and experience of HIV-related stigma), a permissive environment in which it was easy to get away with misreporting, and avoiding inconvenient additional counseling. Some participants also reported mistrust of the staff and reciprocal dishonesty about the study products. Many suggested real-time blood-monitoring during trials would encourage greater fidelity to product use and honesty in reporting. Participants at all sites understood the importance of daily product use and honesty, while also acknowledging widespread misreporting of product use. Narratives of dishonesty may suggest a wider social context of hiding products from partners and distrust about research, influenced by rumors circulating in clinic waiting-rooms and surrounding communities. Prevailing power hierarchies between staff and participants may exacerbate misreporting. Participants recognized and suggested that objective, real-time feedback is needed to encourage honest reporting.

Entities:  

Keywords:  Adherence; Africa; HIV prevention; Honesty; Women

Mesh:

Substances:

Year:  2017        PMID: 27858268      PMCID: PMC5290166          DOI: 10.1007/s10461-016-1609-1

Source DB:  PubMed          Journal:  AIDS Behav        ISSN: 1090-7165


  14 in total

1.  Reporting of Adherence in the VOICE Trial: Did Disclosure of Product Nonuse Increase at the Termination Visit?

Authors:  Barbara S Mensch; Elizabeth R Brown; Karen Liu; Jeanne Marrazzo; Zvavahera Mike Chirenje; Kailazarid Gomez; Jeanna Piper; Karen Patterson; Ariane van der Straten
Journal:  AIDS Behav       Date:  2016-11

Review 2.  Methodological lessons from clinical trials and the future of microbicide research.

Authors:  Ariane van der Straten; Elizabeth T Montgomery; Miriam Hartmann; Alexandra Minnis
Journal:  Curr HIV/AIDS Rep       Date:  2013-03       Impact factor: 5.071

3.  Tenofovir-based preexposure prophylaxis for HIV infection among African women.

Authors:  Jeanne M Marrazzo; Gita Ramjee; Barbra A Richardson; Kailazarid Gomez; Nyaradzo Mgodi; Gonasagrie Nair; Thesla Palanee; Clemensia Nakabiito; Ariane van der Straten; Lisa Noguchi; Craig W Hendrix; James Y Dai; Shayhana Ganesh; Baningi Mkhize; Marthinette Taljaard; Urvi M Parikh; Jeanna Piper; Benoît Mâsse; Cynthia Grossman; James Rooney; Jill L Schwartz; Heather Watts; Mark A Marzinke; Sharon L Hillier; Ian M McGowan; Z Mike Chirenje
Journal:  N Engl J Med       Date:  2015-02-05       Impact factor: 91.245

4.  The science of being a study participant: FEM-PrEP participants' explanations for overreporting adherence to the study pills and for the whereabouts of unused pills.

Authors:  Amy L Corneli; Kevin McKenna; Brian Perry; Khatija Ahmed; Kawango Agot; Fulufhelo Malamatsho; Joseph Skhosana; Jacob Odhiambo; Lut Van Damme
Journal:  J Acquir Immune Defic Syndr       Date:  2015-04-15       Impact factor: 3.731

5.  Adherence and the Lie in a HIV Prevention Clinical Trial.

Authors:  Jonathan Stadler; Fiona Scorgie; Ariane van der Straten; Eirik Saethre
Journal:  Med Anthropol       Date:  2015-11-17

6.  Disclosure of pharmacokinetic drug results to understand nonadherence.

Authors:  Ariane van der Straten; Elizabeth T Montgomery; Petina Musara; Juliane Etima; Sarita Naidoo; Nicole Laborde; Miriam Hartmann; Lisa Levy; Thola Bennie; Helen Cheng; Jeanna Piper; Cynthia I Grossman; Jeanne Marrazzo; Barbara Mensch
Journal:  AIDS       Date:  2015-10-23       Impact factor: 4.177

7.  Contagion and differentiation in unethical behavior: the effect of one bad apple on the barrel.

Authors:  Francesca Gino; Shahar Ayal; Dan Ariely
Journal:  Psychol Sci       Date:  2009-02-23

8.  Preexposure prophylaxis for HIV infection among African women.

Authors:  Lut Van Damme; Amy Corneli; Khatija Ahmed; Kawango Agot; Johan Lombaard; Saidi Kapiga; Mookho Malahleha; Fredrick Owino; Rachel Manongi; Jacob Onyango; Lucky Temu; Modie Constance Monedi; Paul Mak'Oketch; Mankalimeng Makanda; Ilse Reblin; Shumani Elsie Makatu; Lisa Saylor; Haddie Kiernan; Stella Kirkendale; Christina Wong; Robert Grant; Angela Kashuba; Kavita Nanda; Justin Mandala; Katrien Fransen; Jennifer Deese; Tania Crucitti; Timothy D Mastro; Douglas Taylor
Journal:  N Engl J Med       Date:  2012-07-11       Impact factor: 91.245

9.  FEM-PrEP: adherence patterns and factors associated with adherence to a daily oral study product for pre-exposure prophylaxis.

Authors:  Amy L Corneli; Jennifer Deese; Meng Wang; Doug Taylor; Khatija Ahmed; Kawango Agot; Johan Lombaard; Rachel Manongi; Saidi Kapiga; Angela Kashuba; Lut Van Damme
Journal:  J Acquir Immune Defic Syndr       Date:  2014-07-01       Impact factor: 3.731

10.  Divergent adherence estimates with pharmacokinetic and behavioural measures in the MTN-003 (VOICE) study.

Authors:  Ariane van der Straten; Elizabeth R Brown; Jeanne M Marrazzo; Michael Z Chirenje; Karen Liu; Kailazarid Gomez; Mark A Marzinke; Jeanna M Piper; Craig W Hendrix
Journal:  J Int AIDS Soc       Date:  2016-02-04       Impact factor: 5.396

View more
  38 in total

Review 1.  Using Social Networks to Understand and Overcome Implementation Barriers in the Global HIV Response.

Authors:  Guy Harling; Alexander C Tsai
Journal:  J Acquir Immune Defic Syndr       Date:  2019-12       Impact factor: 3.731

2.  Reasons for nonadherence to the dapivirine vaginal ring: narrative explanations of objective drug-level results.

Authors:  Elizabeth T Montgomery; Jonathan Stadler; Sarita Naidoo; Ariana W K Katz; Nicole Laborde; Morgan Garcia; Krishnaveni Reddy; Leila E Mansoor; Juliane Etima; Chifundo Zimba; Miria Chitukuta; Lydia Soto-Torres
Journal:  AIDS       Date:  2018-07-17       Impact factor: 4.177

3.  If You Build It, Will They Use It? Preferences for Antiretroviral Therapy (ART) Adherence Monitoring Among People Who Inject Drugs (PWID) in Kazakhstan.

Authors:  Alissa Davis; Lyailya Sarsembayeva; Valeriy Gulyaev; Sholpan Primbetova; Assel Terlikbayeva; Gaukhar Mergenova; Robert H Remien
Journal:  AIDS Behav       Date:  2019-12

4.  The Role of Volume in the Perceptibility of Topical Vaginal Formulations: User Sensory Perceptions and Experiences of Heterosexual Couples During Vaginal Sex.

Authors:  Kate M Guthrie; Joseph L Fava; Sara E Vargas; Rochelle K Rosen; Julia G Shaw; Erna M Kojic; Anthony S Ham; Lisa C Rohan; David Katz; Anacecilia Panameño; Christopher Colleran; David F Friend; Karen W Buckheit; Robert W Buckheit
Journal:  AIDS Res Hum Retroviruses       Date:  2020-11-03       Impact factor: 2.205

5.  HIV Drug Resistance in Adults Receiving Early vs. Delayed Antiretroviral Therapy: HPTN 052.

Authors:  Philip J Palumbo; Jessica M Fogel; Sarah E Hudelson; Ethan A Wilson; Stephen Hart; Laura Hovind; Estelle Piwowar-Manning; Carole Wallis; Maria A Papathanasopoulos; Mariza G Morgado; Shanmugam Saravanan; Srikanth Tripathy; Joseph J Eron; Joel E Gallant; Marybeth McCauley; Theresa Gamble; Mina C Hosseinipour; Nagalingeswaran Kumarasamy; James G Hakim; Jose H Pilotto; Johnstone Kumwenda; Victor Akelo; Sheela V Godbole; Breno R Santos; Beatriz Grinsztejn; Ravindre Panchia; Suwat Chariyalertsak; Joseph Makhema; Sharlaa Badal-Faesen; Ying Q Chen; Myron S Cohen; Susan H Eshleman
Journal:  J Acquir Immune Defic Syndr       Date:  2018-04-15       Impact factor: 3.731

6.  Sustained-release Griffithsin nanoparticle-fiber composites against HIV-1 and HSV-2 infections.

Authors:  Kevin M Tyo; Amanda B Lasnik; Longyun Zhang; Mohamed Mahmoud; Alfred B Jenson; Joshua L Fuqua; Kenneth E Palmer; Jill M Steinbach-Rankins
Journal:  J Control Release       Date:  2020-02-05       Impact factor: 9.776

7.  Hair levels of preexposure prophylaxis drugs measure adherence and are associated with renal decline among men/transwomen.

Authors:  Monica Gandhi; Pamela M Murnane; Peter Bacchetti; Richard Elion; Michael A Kolber; Stephanie E Cohen; Howard Horng; Alexander Louie; Karen Kuncze; Catherine A Koss; Peter L Anderson; Susan Buchbinder; Albert Liu
Journal:  AIDS       Date:  2017-10-23       Impact factor: 4.177

Review 8.  The Vaginal Microbiome and its Potential to Impact Efficacy of HIV Pre-exposure Prophylaxis for Women.

Authors:  Jennifer Velloza; Renee Heffron
Journal:  Curr HIV/AIDS Rep       Date:  2017-10       Impact factor: 5.071

9.  Behavioral and social science research to support development of educational materials for clinical trials of broadly neutralizing antibodies for HIV treatment and prevention.

Authors:  Pablo K Valente; Yumeng Wu; Yehuda Z Cohen; Marina Caskey; Kathrine Meyers
Journal:  Clin Trials       Date:  2020-08-24       Impact factor: 2.486

10.  Self-administered Versus Directly Observed Once-Weekly Isoniazid and Rifapentine Treatment of Latent Tuberculosis Infection: A Randomized Trial.

Authors:  Robert Belknap; David Holland; Pei-Jean Feng; Joan-Pau Millet; Joan A Caylà; Neil A Martinson; Alicia Wright; Michael P Chen; Ruth N Moro; Nigel A Scott; Bert Arevalo; José M Miró; Margarita E Villarino; Marc Weiner; Andrey S Borisov
Journal:  Ann Intern Med       Date:  2017-11-07       Impact factor: 25.391

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.